npj Breast Cancer

Papers
(The TQCC of npj Breast Cancer is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Author Correction: Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers496
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer251
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab192
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment165
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors118
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer117
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab102
Immunotherapy for early triple negative breast cancer: research agenda for the next decade95
Race-related host and microbe transcriptomic signatures in triple-negative breast cancer89
Biological correlates associated with high-risk breast cancer patients identified using a computational method88
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer83
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer83
C/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells73
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients73
International survey on invasive lobular breast cancer identifies priority research questions66
Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial63
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC61
Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events55
Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer55
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays53
Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell lines52
Breastfeeding attributable fraction of triple negative breast cancer in the US50
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer50
Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice48
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer48
Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer47
Temporal evolution of breast cancer brain metastases treatments and outcomes45
Deep learning radiomics based prediction of axillary lymph node metastasis in breast cancer42
International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)41
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models40
Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions40
Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer40
A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study)38
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases37
Survival outcomes after omission of surgery for ductal carcinoma in situ35
Circulating tumor DNA validity and potential uses in metastatic breast cancer34
Ductal keratin 15+ luminal progenitors in normal breast exhibit a basal-like breast cancer transcriptomic signature34
Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer34
Breast cancer clinical trial participation among diverse patients at a comprehensive cancer center33
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer32
Cancer risk assessment of premalignant breast tissues from patients with BRCA mutations by genome profiling32
Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification32
Understanding metastasis mixed-treatment responses through genomic analyses32
Kataegis in clinical and molecular subgroups of primary breast cancer32
Is conservative management of ductal carcinoma in situ risky?32
Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment31
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer30
The cytosolic iron–sulfur cluster assembly (CIA) pathway is required for replication stress tolerance of cancer cells to Chk1 and ATR inhibitors30
Trends in contralateral breast cancer and contralateral prophylactic mastectomy from 2009 to 201630
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models30
Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program29
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment29
Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer29
ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance29
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer29
GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer27
Large language model (ChatGPT) as a support tool for breast tumor board26
Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies26
ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin26
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled 26
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer25
Cook and Move for Your Life, an eHealth intervention for women with breast cancer25
Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study25
A systematic review of determinants of breast cancer risk among women with benign breast disease24
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy24
PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer23
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer22
A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer22
Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis22
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies22
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models22
The 21-gene recurrence score in early non-ductal breast cancer: a National Cancer Database analysis21
Predicting short- to long-term breast cancer risk from longitudinal mammographic screening history21
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers21
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer21
Prognostic value of structural variants in early breast cancer patients21
Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study20
Personalized neoadjuvant strategy using 70-gene assay to increase breast-conserving surgery in ER+/HER2– breast cancer20
Increased trunk fat is associated with altered gene expression in breast tissue of normal weight women20
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence19
Evaluating mammographic density′s contribution to improve a breast cancer risk model with questionnaire-based and polygenic factors19
ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation19
Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor19
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer19
MRI background parenchymal enhancement, breast density and breast cancer risk factors: A cross-sectional study in pre- and post-menopausal women18
Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases18
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry18
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape18
Subclonal heterogeneity and evolution in breast cancer18
Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy18
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response17
Assessment of MRI to estimate metastatic dissemination risk and prometastatic effects of chemotherapy17
Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention17
Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer17
Author Correction: Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer17
Racial discrimination among women seeking breast cancer care17
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study17
Plasma extracellular vesicle long RNA profiles in the diagnosis and prediction of treatment response for breast cancer17
Plasma C-peptide mammographic features and risk of breast cancer17
Immunologically “cold” triple negative breast cancers engraft at a higher rate in patient derived xenografts16
Association between ancestry and tumor somatic mutations in a large national cohort of women with breast cancer16
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer16
Artificial intelligence in breast pathology – dawn of a new era16
Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib16
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer16
The different prognostic significance of polysialic acid and CD56 expression in tumor cells and lymphocytes identified in breast cancer16
Development and validation of a clinical breast cancer tool for accurate prediction of recurrence16
Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer16
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer16
Post-diagnosis weight trajectories and mortality among women with breast cancer16
Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study16
Proteogenomic characterization of invasive breast tumors in young women16
Genomic landscape of breast cancer in elderly patients15
Author Correction: Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics15
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer15
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer15
Advancing equitable access to innovation in breast cancer15
Predicting early breast cancer recurrence from histopathological images in the Carolina Breast Cancer Study15
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings15
Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial15
Genomic landscapes of breast cancer in African populations: a systematic review15
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer15
0.17301678657532